Whitefish, MT / May 9, 2014 / Biotechnology stocks have had a rough quarter, with the iShares NASDAQ Biotechnology Index ETF (IBB) falling more than 6% since February. Investors have started to re-evaluate the sector’s lofty valuations, while higher interest rates in the near future could slow the M&A frenzy. As a result, investors may want to shift their attention to high-growth bargains in the industry.
Premier Biomedical Inc. (BIEI), a biopharmaceutical company focused on developing innovative immune system manipulation therapies, is on the cusp of beginning wide scale animal and human clinical trials that could catalyze the stock upwards after three years of quietly developing its technology. With the recent correction in biotechnology stocks, investors may want to take a closer look.
Premier Biomedical recently announced that they have initiated discussions with the William Beaumont Army Medical Center. After a three year vetting process, the team believes that the U.S. Department of Defense is ready to begin staged clinical trials to evaluate the safety and efficacy of its technology in treating post traumatic stress disorder (“PTSD”) and suicidal/homicidal ideations.
PTSD and suicidal/homicidal ideations are typically treated with anti-depressants and anti-psychotics like Pfizer Inc.’s (PFE) Geodon(r). With an affinity for most dopamine and serotonin receptors, the pharmaceutical drug works by acting as an antagonist/inverse agonist of the receptors. Many of these pharmaceuticals, including Geodon®, have black box warnings for their severe side effects.
Premier Biomedical’s researchers are taking a different approach by removing specific molecular compounds thought to be responsible for the conditions from cerebral-spinal fluid using a dialysis-like process. For example, inflammatory cytokines have been associated with suicide and depression, and Premier Biomedical has already successfully removed these cytokines with picogram-level accuracy.
According to the Veterans Administration, one active-duty person per day commits suicide due to these ideations. These figures jump to almost one suicide per hour every day throughout the year when including veterans. Premier Biomedical’s partnership with the U.S. DoD provides both a large patient population available for clinical trials and the possibility of a speedy FDA approval, thereby easing shareholder cost.
In addition to its work with the U.S. DoD, Premier Biomedical has been partnered with researchers from the University of Texas El Paso (“UTEP”) to develop treatments for a number of other diseases and conditions, including Alzheimer’s diseases, traumatic brain injury (“TBI”) and breast cancer. These indications represent billions of dollars of additional potential if safe, efficacious, and approved.
Many past attempts at developing drugs for these conditions have been unsuccessful. For instance, many beta amyloid inhibitors and pharmaceutical therapies for Alzheimer’s disease have failed late-stage clinical trials, such as Eli Lilly & Co.’s (LLY) solanezumab. The failure of these drugs suggests that a different approach may be needed to tackle the conditions.
The company’s technology works in the same was as it does with the U.S. DoD project – harmful compounds associated with these diseases are removed from the body through a dialysis-like process. For instance, metastatic cancer cells or tau proteins are cycled outside of the body, sequential dialysis-like processes are used to purify the patient’s blood, and the cleaned blood is returned to the body.
With animal studies already underway, management plans to begin human clinical trials as early as next quarter as a follow-up to their successful experiments on breast cancer in mice presented at the Annual Symposium of the American Association for Cancer Research in San Diego in April. More importantly, attempts at re-infecting a subset of the mice with breast cancer failed, further suggesting the successful manipulation of the immune system by Premier’s process. The treatments could become preferred options over harmful alternatives like chemotherapy.
Premier Biomedical Inc. (BIEI) trades with a market capitalization of under $10 million despite its potential to disrupt multiple billion-dollar markets. Through its partnerships with the U.S. DoD and UTEP, the company is well positioned to prudently advance its research and unlock long-term value for shareholders by addressing indications ranging from depression to cancer.
For more information, see the following resources:
Get Updates on Premier Biomedical here: http://www.tdmfinancial.com/emailassets/biei/biei_landing.php
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx
- Health Care Industry
- clinical trials